secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0001558370-24-013486
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea reports preliminary Phase 1 safety data for WEE1 inhibitor APR-1051; no hematologic toxicity
--------------------------------------------------------------------------------

- APR-1051 safe and well-tolerated in first three patients; all adverse events Grade 1-2, no neutropenia or QT prolongation.
- Phase 1 ACESOT-1051 study evaluating 10–150 mg daily doses; 8 cohorts planned, subtherapeutic doses given in cohorts 1-3.
- Data cutoff Oct 7, 2024: one patient progressed at 49 days, one withdrew at 36 days, third continues on treatment.
- Active enrollment at 3 U.S. sites (NEXT Oncology in San Antonio & Dallas, MD Anderson); preliminary efficacy data expected in 2025.
- APR-1051 designed for selective WEE1 inhibition without PLK off-target effects seen with other WEE1 inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024013486/0001558370-24-013486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024013486/apre-20241023x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer